GLP-1 Receptor Agonists Market Value Projected to Expand by 2029
GLP-1 receptor agonists market is anticipated to showcase a considerable CAGR during the forecast period. The increasing R&D and huge investment by the major market players for the development of new products along with the high prevalence of type 2 diabetic patients across the globe are the key factors responsible for the high growth of the GLP-1 receptor agonists market across the globe. GLP-1 receptor agonists are a category of antidiabetic agents that performs functioning of the glucagon-like peptide. GLP-1 is a natural incretin compound that influences the body functioning once they get released from the gut during digestion.
The combination of GLP-1 receptors, GLP-1 agonists,
and endogenous GLP-1 is capable to reduce blood glucose levels to facilitate
Type 2 diabetes patients to reach glycemic control. The proper intake of
the GLP-1 receptor agonists increases the glucose-dependent secretion of
insulin from functioning beta cells. Moreover, its intake decreases the
glucagon release after meals, decrease hepatic glucose production, delayed
gastric emptying, suppress the appetite and promotes beta-cell proliferation.
According to the International Diabetic Federation (IDF) in 2019, nearly 463
million adults (20-79 years) were living with diabetes across the globe and
this figure is anticipated to reach 700 million by 2045.
Diabetes is responsible for nearly $760 billion in
health expenditure in 2019 that resembles 10% of total spending on adults for
their health treatment. In 2019, 374 million people are observed to be at an
increased risk of developing type 2 diabetes. The considerably high prevalence
of this chronic disorder is creating the demand for the market growth of the
GLP-1 receptor agonists. Bristol Mayer Squibb, Novo Nordisk A/S, Sanofi SA, Eli
Lilly & Company, AstraZeneca PLC, and Merck & Co., Inc are the key
players operating in the global GLP-receptor agonists market that are making
hefty investments in the R&D of new drugs. Moreover, these players are
actively adopting other growth strategies such as mergers & acquisitions,
strategic agreements, partnerships, and collaborations in order to remain competitive
in the global GLP-1 receptor agonists market.
To Request a Sample of our Report on GLP-1 Receptor Agonists Market: https://www.omrglobal.com/request-sample/glucagon-like-peptide-1-glp-1-receptor-agonists-market
GLP-1 Receptor Agonists Market
Segmentation
By Drug Type
- Exenatide
- Liraglutide
- Lixisenatide
- Dulaglutide
A full report of GLP-1
Receptor agonists Market is available at: https://www.omrglobal.com/industry-reports/glucagon-like-peptide-1-glp-1-receptor-agonists-market
GLP-1 Receptor agonists
Market– Segment by Region
North
America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AstraZeneca PLC
- Bristol Mayer Squibb, Co.
- Eli Lilly & Company
- Merck & Co., Inc.
- Novo Nordisk A/S
- Sanofi SA
Reasons to Buy From us –
- We cover more than 15 major industries,
further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for
investigation.
- Our expert research analysts answer all your
questions before and after purchasing your report.
About Orion Market
Research
Orion Market Research (OMR) is a market research
and consulting company known for its crisp and concise reports. The company is
equipped with an experienced team of analysts and consultants. OMR offers
quality syndicated research reports, customized research reports, consulting
and other research-based services.
Media Contact:
Contact Person: Mr. Anurag
Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market
Research
Comments
Post a Comment